CN100563644C - A kind of carmustine sustained-release implantation agent for the treatment of entity tumor - Google Patents
A kind of carmustine sustained-release implantation agent for the treatment of entity tumor Download PDFInfo
- Publication number
- CN100563644C CN100563644C CNB2007102028853A CN200710202885A CN100563644C CN 100563644 C CN100563644 C CN 100563644C CN B2007102028853 A CNB2007102028853 A CN B2007102028853A CN 200710202885 A CN200710202885 A CN 200710202885A CN 100563644 C CN100563644 C CN 100563644C
- Authority
- CN
- China
- Prior art keywords
- carmustine
- release
- poly
- lactide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 title claims abstract description 211
- 229960005243 carmustine Drugs 0.000 title claims abstract description 210
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 125
- 238000013268 sustained release Methods 0.000 title claims abstract description 81
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 81
- 238000002513 implantation Methods 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 239000007943 implant Substances 0.000 claims abstract description 77
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 44
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 39
- 229930195725 Mannitol Natural products 0.000 claims abstract description 39
- 239000000594 mannitol Substances 0.000 claims abstract description 39
- 235000010355 mannitol Nutrition 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 29
- 230000001093 anti-cancer Effects 0.000 claims abstract description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 58
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 52
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 52
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 52
- 239000002253 acid Substances 0.000 claims description 45
- 239000011780 sodium chloride Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 42
- 229940079593 drug Drugs 0.000 abstract description 33
- 238000000034 method Methods 0.000 abstract description 26
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract description 24
- 239000000600 sorbitol Substances 0.000 abstract description 24
- 235000010356 sorbitol Nutrition 0.000 abstract description 24
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 13
- 229920002101 Chitin Polymers 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- -1 chrondroitin Substances 0.000 abstract description 3
- 229920002521 macromolecule Polymers 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 159000000000 sodium salts Chemical class 0.000 abstract description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 2
- 102000009027 Albumins Human genes 0.000 abstract description 2
- 108010088751 Albumins Proteins 0.000 abstract description 2
- 102000008186 Collagen Human genes 0.000 abstract description 2
- 108010035532 Collagen Proteins 0.000 abstract description 2
- 108010010803 Gelatin Proteins 0.000 abstract description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract description 2
- 229920000159 gelatin Polymers 0.000 abstract description 2
- 239000008273 gelatin Substances 0.000 abstract description 2
- 235000019322 gelatine Nutrition 0.000 abstract description 2
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 2
- 229920002674 hyaluronan Polymers 0.000 abstract description 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 abstract description 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract description 2
- 239000000811 xylitol Substances 0.000 abstract description 2
- 235000010447 xylitol Nutrition 0.000 abstract description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract description 2
- 229960002675 xylitol Drugs 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 description 22
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 150000003904 phospholipids Chemical class 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 206010008342 Cervix carcinoma Diseases 0.000 description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 201000010881 cervical cancer Diseases 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 201000005619 esophageal carcinoma Diseases 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 201000001514 prostate carcinoma Diseases 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 201000003914 endometrial carcinoma Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 201000010174 renal carcinoma Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Embodiment one | 1 day | 3 days | 5 days | 7 days | 14 days | 21 days | 28 days | 35 days | 42 days | 56 days | 63 days |
(A) | 2.2 | 7.5 | 14 | 30 | 68 | 86 | 98 | 100 | 100 | 100 | 100 |
(a) | 2 | 8 | 14 | 20 | 40 | 50 | 60 | 72 | 84 | 96 | 98 |
(B) | 2.2 | 12 | 18 | 31 | 60 | 86 | 92 | 98 | 100 | 100 | 100 |
(b) | 2.4 | 12 | 18 | 24 | 48 | 54 | 62 | 76 | 88 | 96 | 100 |
(C) | 2.1 | 9 | 15 | 28 | 60 | 84 | 98 | 100 | 100 | 100 | 100 |
(c) | 2.3 | 7.9 | 16 | 23.6 | 42.8 | 56 | 64 | 78 | 84 | 92 | 96 |
(D) | 3.2 | 8 | 17.2 | 36.8 | 62 | 88 | 98 | 100 | 100 | 100 | 100 |
(d) | 3 | 7.2 | 18 | 24 | 41 | 52 | 68 | 80 | 90 | 98 | 100 |
(E) | 3.1 | 13.0 | 19.0 | 47.3 | 68.2 | 94 | 98 | 100 | 100 | 100 | 100 |
(e) | 3 | 11 | 18 | 26.0 | 39 | 52 | 68 | 82 | 88 | 94 | 96 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007102028853A CN100563644C (en) | 2007-12-06 | 2007-12-06 | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007102028853A CN100563644C (en) | 2007-12-06 | 2007-12-06 | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101176707A CN101176707A (en) | 2008-05-14 |
CN100563644C true CN100563644C (en) | 2009-12-02 |
Family
ID=39403228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007102028853A Expired - Fee Related CN100563644C (en) | 2007-12-06 | 2007-12-06 | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100563644C (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103610670A (en) * | 2013-11-04 | 2014-03-05 | 鲁东大学 | Application of carmustin in preparation of medicine for treating lymjphoma |
CN107375246B (en) * | 2017-07-21 | 2019-10-08 | 浙江理工大学 | A kind of polymer nano-particle preparation method of the load anticancer drug with targeting controlled release function |
WO2019094819A2 (en) * | 2017-11-09 | 2019-05-16 | Abon Pharmaceuticals, Llc | Intravenous delivery systems for chemotherapy drugs |
-
2007
- 2007-12-06 CN CNB2007102028853A patent/CN100563644C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101176707A (en) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101185633A (en) | Neratinib sustained-release implant for treating solid tumor | |
CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
CN101176713B (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
CN101185627B (en) | Nilotinib sustained-release implant for treating solid tumor | |
CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
CN100563645C (en) | A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor | |
CN101204366A (en) | Melphalan sustained-release implant treating for solid tumor | |
CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
CN101176714A (en) | Meifaron sustained-release implantation agent for curing entity tumour | |
CN100586435C (en) | Carmofur sustained-release implantation agent for curing entity tumour | |
CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
CN101176712A (en) | Nimustine sustained-release implantation agent for curing entity tumour | |
CN101181231B (en) | Sustained-release implantation agent of urotrotiken | |
CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors | |
CN101185625B (en) | Rubitecan sustained-release implant for treating solid tumor | |
CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
CN101185632A (en) | Lonafarnib sustained-release implant for treating solid tumor | |
CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour | |
CN101176710A (en) | Mitoxantrone sustained-release implantation agent for curing entity tumour |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD. Effective date: 20120815 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120815 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091202 Termination date: 20161206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |